COMMUNIQUÉS West-GlobeNewswire

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
30/04/2026
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a [...]
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
30/04/2026
Press Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S [...]
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
30/04/2026
Ghent, Belgium – April 30, 2026 – Confo Therapeutics , a leader in the development of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first patients were dosed in a Phase 2a clinical [...]
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
30/04/2026
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , société pharmaceutique spécialisée en phase avancée de développement et [...]
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
30/04/2026
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , société pharmaceutique spécialisée en phase avancée de développement et [...]
Disclosure of transparency notification from BlackRock, Inc.
30/04/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 April 2026 – 6 PM CET Disclosure of transparency notification from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of [...]
SPINEWAY :
30/04/2026
Ecully, le 30 avril 2026 – 18h00 Chiffre d’affaires du 1er trimestre 2026 Niveau de commandes élevé Normalisation plus lente que prévue des approvisionnements 2026 : trajectoire de croissance confirmé En milliers d’ [...]
Spineway : First-quarter 2026 revenue
30/04/2026
Ecully, April 30, 2026 – 6:00 p.m. First-quarter 2026 revenue High order volume Slower-than-expected normalization of supply chains 2026: growth trajectory confirmed In thousands of euros 2026 2025 Change as a % Q1 [...]
KAI Conversations Announces Strategic Partnership with Syneos Health to Advance U.S. Pharmaceutical Commercialization
30/04/2026
AI-Driven Field Insights Drive Pharmaceutical Brand Performance in World’s Largest Market LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- KAI Conversations, an AI-powered conversation intelligence platform purpose-built for [...]
Ocubio Announces Appointment of Jim Mazzo and Dr. Eric Donnenfeld as Strategic Advisors
30/04/2026
MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- Ocubio, a biotechnology company advancing personalized, biologic-based therapies for ocular surface disease, today announced the appointment of James V. Mazzo and Eric D. [...]
Sofanya Launches Highly Anticipated Sacred Body Oil Just in Time for Mother's Day: 'this isn't about doing more, it's about coming back'
30/04/2026
At the intersection of science and the Divine Feminine, Sofanya creates body care and wellness products that merge cellular nourishment with sacred ritual. Los Angeles, CA, April 30, 2026 (GLOBE NEWSWIRE) -- This Mother [...]
RAPPORT FINANCIER 2025
30/04/2026
RAPPORT FINANCIER 2025 Pièces jointes RAPPORT FINANCIER 2025 RAPPORT FINANCIER 2025
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS ANNUELS ET SON RAPPORT ANNUEL
30/04/2026
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS ANNUELS ET SON RAPPORT ANNUEL Berlin, Allemagne, le 30 avril 2026, 20 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), Une société de biotechnologie en phase [...]
TME Pharma publishes its annual financial results and annual report
30/04/2026
TME Pharma publishes its annual financial results and annual report Berlin, Germany , April 30, 2026, 20.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in [...]
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
30/04/2026
RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three [...]
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
30/04/2026
NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver [...]
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
30/04/2026
LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB: OTLC), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, [...]
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
30/04/2026
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant [...]
Spectral AI Wins Small Business Innovator Award at Inaugural Texas Innovation Conference
30/04/2026
DALLAS, April 30, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]

Pages